Imigran-Inject

Sumatriptan succinate, the active ingredient in Imigran-Inject, is a Triptan (5-HT1B/1D receptor agonist) presented as an injectable solution for subcutaneous use. It provides acute treatment of migraine attacks in adults. GNH USA supplies Imigran-Inject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran-Inject, a selective serotonin 5‑HT1B/1D receptor agonist, is used for conditions where rapid relief of vascular headache is required.

Migraine: alleviates pain and associated symptoms during an acute migraine attack. Migraine with aura: reduces headache intensity and associated neurological disturbances. Cluster headache: provides acute relief during episodic cluster headache attacks.

Imigran-Inject may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Injection site pain or erythema - Tingling or numbness in the face or extremities - Warmth or flushing sensation - Nausea or mild dizziness

Serious or Rare Side Effects: - Chest discomfort or tightness - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with other serotonergic agents - Allergic reactions such as rash, angioedema, or anaphylaxis - Cardiac arrhythmias or myocardial ischemia

Before prescribing Imigran-Inject, clinicians should consider several safety aspects.

Cardiovascular assessment: evaluate for history of coronary artery disease or uncontrolled hypertension. Contraindication review: avoid use in patients with known hypersensitivity to sumatriptan or other triptans. Serotonergic risk: assess concurrent use of other serotonergic drugs to prevent serotonin syndrome. Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. Monitoring: observe for signs of chest pain, severe hypertension, or allergic reactions after administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan may interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): heightened serotonin toxicity. - Ergot alkaloids: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: possible additive blood pressure lowering. - CYP3A4 inhibitors (ketoconazole, erythromycin): may raise sumatriptan plasma levels. - Oral contraceptives: may slightly increase migraine frequency; monitor efficacy.